Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 34, Issue 20, 2016, Pages 2389-2397

  Goff, Stephanie L ^a   Dudley, Mark E ^c   Citrin, Deborah E ^a   Somerville, Robert P ^a   Wunderlich, John R ^a   Danforth, David N ^a   Zlott, Daniel A ^b   Yang, James C ^a   Sherry, Richard M ^a   Kammula, Udai S ^a   Klebanoff, Christopher A ^a   Hughes, Marybeth S ^a   Restifo, Nicholas P ^a   Langhan, Michelle M ^a   Shelton, Thomas E ^a   Lu, Lily ^a   Kwong, Mei Li M ^a   Ilyas, Sadia ^a   Klemen, Nicholas D ^a   Payabyab, Eden C ^a   Morton, Kathleen E ^a   Toomey, Mary Ann ^a   Steinberg, Seth M ^a   White, Donald E ^a   Rosenberg, Steven A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL STUDY; CONTROLLED STUDY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; HUMAN CELL; LENGTH OF STAY; LYMPHOCYTE TRANSFER; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SEPSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT REDUCTION; WHOLE BODY RADIATION; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; COMPARATIVE STUDY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MELANOMA; METASTASIS; MORTALITY;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; WHOLE-BODY IRRADIATION;

EID: 84977573737     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.7220     Document Type: Article

References (35)

1. American Cancer Society: Cancer Facts and Figures 2015. Atlanta, GA, American Cancer Society, 2015
2. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45:8-30, 1995
3. Smith FO, Downey SG, Klapper JA, et al: Treatment of metastatic melanoma using interleukin- 2 alone or in conjunction with vaccines. Clin Cancer Res 14:5610-5618, 2008
4. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985
5. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994
6. Dudley ME, Wunderlich JR, Yang JC, et al: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigenspecific T lymphocytes in patients with metastatic melanoma. J Immunother 25:243-251, 2002
7. Besser MJ, Shapira-Frommer R, Itzhaki O, et al: Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19:4792-4800, 2013
8. Pilon-Thomas S, Kuhn L, Ellwanger S, et al: Efficacy of adoptive cell transfer of tumorinfiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35:615-620, 2012
9. Radvanyi LG, Bernatchez C, Zhang M, et al: Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758-6770, 2012
10. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005
11. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-4557, 2011
12. Wrzesinski C, Paulos CM, Kaiser A, et al: Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumorspecific T cells. J Immunother 33:1-7, 2010
13. Dudley ME, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239, 2008
14. Dudley ME, Wunderlich JR, Shelton TE, et al: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342, 2003
15. Goff SL, Smith FO, Klapper JA, et al: Tumor infiltrating lymphocyte therapy for metastatic melanoma: Analysis of tumors resected for TIL. J Immunother 33:840-847, 2010
16. Agresti A: Categorical data analysis. New York, NY, Wiley, 1990
17. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r 3 c contingency tables. J Am Stat Assoc 78:427-434, 1983
18. Tseng J, Citrin DE, Waldman M, et al: Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer 120:1426-1432, 2014
19. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101:4260-4266, 2003
20. Zhou J, Shen X, Huang J, et al: Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175:7046-7052, 2005
21. Ferrucci PF, Ascierto PA, Pigozzo J, et al: Baseline neutrophils and derived neutrophil-tolymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 27:732-738, 2016
22. Diem S, Kasenda B, Spain L, et al: Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114:256-261, 2016
23. Lu YC, Yao X, Crystal JS, et al: Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 20:3401-3410, 2014
24. Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-752, 2013
25. Gros A, Robbins PF, Yao X, et al: PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124: 2246-2259, 2014
26. + T cells in a patient with epithelial cancer. Science 344:641-645, 2014
27. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
28. Schadendorf D, Hodi FS, Robert C, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889-1894, 2015
29. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
30. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
31. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (Check Mate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384, 2015
32. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330, 2015
33. Robert C, Ribas A, Wolchok JD, et al: Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
34. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
35. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015